About Glutaredoxin domain-containing cysteine-rich protein 1
Glutaredoxin domain-containing cysteine-rich protein 1 (GRXCR1) is a protein
from Homo sapiens identified by UniProt accession
A8MXD5, 290 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | Glutaredoxin domain-containing cysteine-rich protein 1 |
|---|
| UniProt accession | A8MXD5 |
|---|
| Gene | GRXCR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 290 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (56)
Diseases linked to this target (Open Targets).
- deafness · score 0.65
- hearing loss, autosomal recessive · score 0.64
- Rare genetic deafness · score 0.41
- nonsyndromic genetic hearing loss · score 0.37
- hearing loss · score 0.37
- protein measurement · score 0.28
- breast milk measurement · score 0.28
- Hearing impairment · score 0.27
- genetic disorder · score 0.19
- schizophrenia · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A8MXD5-F1 | alphafold | PREDICTED | 74.66 | — |
Amino-acid sequence (290 residues)
MLKREMKPES DRPRKVRFRI ASSHSGRVLK EVYEDGQPSG SLDSECASIC GIDGLGDSDG QQNGHIESEG DENENDQDSL LVLARAASEK GFGTRRVNIL SKNGTVRGVK YKVSAGQALF NNLTKVLQQP STDLEFDRVV IYTTCLRVVR TTFERCELVR KIFQNHRVKF EEKNIALNGE YGKELDERCR RVSEAPSLPV VFIDGHYLGG AEKILSMNES GELQDILTKI ERVQHPHECP SCGGFGFLPC SVCHGSKMSM FRNCFTDSFK ALKCTACNEN GLQRCKNCAG
Explore Glutaredoxin domain-containing cysteine-rich protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets